Status:
UNKNOWN
MRI Contrast Clearance Analysis for Glioma Grading and Genotyping
Lead Sponsor:
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Conditions:
Glioma
Eligibility:
All Genders
Brief Summary
Gliomas are the most common primary brain tumor. Gliomas with different grades have different clinical behaviors that determine treatment planning and patient prognosis in clinical practice. In the 20...
Detailed Description
This is a single-center bidirectional cohort study. The subjects of this study were patients diagnosed as glioma by pathological biopsy. Patients with suspicious mass will be performed extra 30 and 60...
Eligibility Criteria
Inclusion
- Patients with brain space -occupying lesions, have not yet undergone antitumor therapy;
- MRI with T1-contract delayed sequence was performed less than 2 weeks before surgery;
- Definite histopathologic diagnosis of glioma.
Exclusion
- WHO 1 gliomas and other non-glioma brain tumors;
- Poor image quality and heavy artifact affect the subsequent image processing.
Key Trial Info
Start Date :
June 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 30 2024
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06018870
Start Date
June 1 2023
End Date
June 30 2024
Last Update
August 31 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sang Zifan
Chongqing, Chongqing Municipality, China, 400042